Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

13.07
-0.5400-3.97%
Post-market: 13.100.0300+0.23%19:58 EDT
Volume:5.65M
Turnover:74.04M
Market Cap:1.29B
PE:-2.24
High:13.59
Open:13.56
Low:12.88
Close:13.61
52wk High:39.89
52wk Low:12.88
Shares:98.32M
Float Shares:80.72M
Volume Ratio:1.21
T/O Rate:7.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-4.42
PE(LYR):-2.24

Loading ...

Ultragenyx price target lowered to $37 from $83 at Canaccord

TIPRANKS
·
Sep 03

Ultragenyx price target lowered to $25 from $50 at H.C. Wainwright

TIPRANKS
·
Sep 03

Stocks to Watch: Snowflake, Broadcom, HPE, Ultragenyx

Dow Jones
·
Sep 03

Ultragenyx Pharma is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Sep 03

Ultragenyx Pharmaceutical Shares Crash 45% After Angelman Syndrome Drug Trial Disappoints

Trading Random
·
Sep 03

Ultragenyx Pharmaceutical Inc. : Baird Cuts to Neutral Rating; Cuts Target Price to $16 from $40

THOMSON REUTERS
·
Sep 03

Ultragenyx Pharmaceutical Inc. : TD Cowen Cuts Target Price to $18 from $49

THOMSON REUTERS
·
Sep 03

Ultragenyx Pharmaceutical Inc. : Canaccord Genuity Cuts Target Price to $37 from $83

THOMSON REUTERS
·
Sep 03

Ultragenyx downgraded to In Line from Outperform at Evercore ISI

TIPRANKS
·
Sep 03

Evercore ISI downgrades Ultragenyx Pharmaceutical (RARE) to a Hold

TIPRANKS
·
Sep 03

Ultragenyx downgraded to Market Perform from Outperform at William Blair

TIPRANKS
·
Sep 03

William Blair downgrades Ultragenyx Pharmaceutical (RARE) to a Hold

TIPRANKS
·
Sep 03

Ultragenyx Says Phase 3 Study on Rare Neurogenetic Disorder Missed Primary, Secondary Endpoints; Shares Fall After-Hours

MT Newswires Live
·
Sep 03

Ultragenyx Pharmaceutical to Cut Costs After Drug Trial Misses Endpoints

Dow Jones
·
Sep 03

Ultragenyx's Rare Disease Drug Fails in Late-Stage Trial

Reuters
·
Sep 03

Ultragenyx Announces Phase 3 Aspire Results in Angelman Syndrome

THOMSON REUTERS
·
Sep 03

Ultragenyx Pharmaceutical - Safety Profile in Aspire Study Consistent with Phase 1/2

THOMSON REUTERS
·
Sep 03

Ultragenyx Pharmaceutical - to Evaluate Apazunersen Program and Implement Significant Expense Reductions

THOMSON REUTERS
·
Sep 03

Ultragenyx Pharmaceutical - Expects to Continue Toward Profitability in 2027

THOMSON REUTERS
·
Sep 03

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

GlobeNewswire
·
Sep 03